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Case Presentation:
Darkening and Eruptive Nevi During Treatment With Erlotinib 
Discussion:
Erlotinib is a small molecule tyrosine kinase inhibitor that functions by blocking the 
intracellular portion of the epidermal growth factor receptor (EGFR). This blockade 
prevents tyrosine kinase phosphorylation and the activation of the mitogen-activated 
protein kinase (MAPK) signaling pathway involved in cell growth and proliferation. EGFR 
is found in the basal layer of the epidermis, sweat glands, and hair follicles, and is 
overexpressed in some cancers. Erlotinib is indicated in the treatment of non-small cell 
lung cancer and advanced stage pancreatic cancer. A number of cutaneous side effects 
have been reported including an acneiform eruption (63%), xerosis (7.7%), pruritus (3.8%), 
and paronychia (6%).
Eruptive nevi have been reported in one patient treated with erlotinib, and in seven 
patients treated with sorafenib, a multikinase inhibitor that also affects the MAPK 
pathway. Vemurafenib, a selective inhibitor of BRAF in the MAPK pathway, has been 
reported to produce dysplastic nevi, melanomas, eruptive nevi, and darkening of existing 
nevi. Changes in nevi were noted within a few months of initiating treatment with 
these medications. The effects of vemurafenib have been ascribed to a paradoxical up-
regulation of MAPK, which has been well documented and demonstrated in vivo. Perhaps 
erlotinib has a similar potential to paradoxically up-regulate MAPK or other enzymes in the 
pathway, thus stimulating cellular proliferation and survival.
We decided to investigate c-KIT, a tyrosine kinsae receptor that activates the MAPK 
pathway and is critical to the development and survival of melanocytes. Stimulation of 
c-KIT tyrosine kinase can also induce melanocyte proliferation and pigment production/
melanogenesis. Activating mutations of c-KIT have been described in some cases of 
melanoma.  In our patient, c-KIT immunostaining revealed a mild to moderate increase 
in intensity in nevi and melanomas post-darkening compared to similar pre-darkened 
lesions. Increased expression of c-KIT, possibly reactive to downstream inhibition of the 
MAPK pathway from erlotinib, could be implicated in our case of eruptive nevi. 
To our knowledge, this is the first reported case of darkening of existing nevi, eruptive 
nevi, and melanoma in situ during treatment with erlotinib. The timeline and clinical 
similarities to previous reports of changes in nevi with other agents affecting the MAPK 
pathway provide support for erlotinib as the causative agent in our patient. We therefore 
suggest frequent full body cutaneous examinations to monitor for possible melanocytic 
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Patient: 70 year-old Caucasian male. 
History of Present Illness: Our patient 
developed eruptive nevi and darkening of his existing 
nevi three months after beginning erlotinib for treatment 
of non-small cell lung carcinoma. The patient’s prior 
chemotherapeutic regimen was discontinued five weeks 
before starting erlotinib. A complete cutaneous exam after 
completion of these chemotherapeutic agents and prior 
to initiation of erlotinib was unremarkable for abnormally 
dark or eruptive nevi. Of note, the patient had not had 
a melanoma diagnosed since 2006. However, since the 
start of erlotinib the patient had ten biopsies performed on 
clinically suspicious dark nevi, two of which were favored 
to be melanoma in situ and one an atypical nevus. 
Medical History/Surgical History: Non-
small cell lung cancer (May 2012), invasive melanomas 
x3, atypical nevi, hypertension, diabetes, diverticulitis, 
gastroesophageal reflux disease, chronic obstructive 
pulmonary disease, left lower lobectomy and lymph 
node dissection (July 2012), pacemaker and defibrillator 
placement, gastric bypass, appendectomy, cholecystectomy
Medications: Erlotinib (started May 2013), 
lansoprazole, fosinopril, metformin, aspirin, simvastatin, 
niacin, nifedipine, bisoprolol fumarate/hydrochlorothiazide, 
furosemide 
Previous Lung Cancer Treatments: 
Docetaxel, carboplatin, and pegfilgrastim (9/2012 - 
11/2012), decadron and palonosetron (9/2012 - 4/2013), 
pemetrexed (3/2013 - 4/2013)
Physical Examination: Numerous dark brown 
to black macules on the trunk and bilateral extremities. 
Scattered papules and pustules with generalized xerosis on 
the trunk and extremities.
Studies: c-KIT immunostaining revealed a mild to 
moderate increase in intensity in nevi and melanomas 
post-darkening compared to similar pre-darkened lesions.
Biopsy: Advanced Dermatology Associates, LTD 
(AD13-08457, 8/22/2013); Right posterior shoulder: 
“Population of heavily pigmented, keratinocyte-sized 
melanocytes in coalescing, ill-defined, junctional and 
intraepidermal aggregates of varying morphology. 
Additionally, there is a population of solitary melanocytes 
scattered throughout the spinous zone.”
Advanced Dermatology Associates, LTD (AD13-12842, 
12/12/2013); Right posterior shoulder: “Junctional nests of 
plump spindled melanocytes varying in size and shape are 
crowded throughout with focal coalescence.”
Figure 1A: July 2010: Patient’s back before treatment with erlotinib (started May, 2013).
Figure 1B: Dec. 2013: Patient’s back demonstrating darkened and eruptive nevi during treatment with erlotinib (started May, 2013).
Figure 2: Timeline and clinical photos demonstrating changes in nevi in relation to chemotherapeutic treatments.
Figure 3A: December 2013: Clinical image of a melanoma in situ on the right posterior shoulder.
Figure 3B: H&E 20x December 2013: Right posterior shoulder: Melanoma in situ. “Junctional nests of plump spindled 
melanocytes varying in size and shape are crowded throughout with focal coalescence.”
Figure 4A: c-KIT 20x July 2010: Left nasal sidewall: Melanocytic nevus, compound. “c-KIT immunostaining of a nevus before 
treatment with erlotinib demonstrating weak staining of the dermal melanocytes.”
Figure 4B: c-KIT 20x December 2013: Right lateral back: Melanocytic nevus, compound. “c-KIT immunostaining of a darkened 
nevus during treatment with erlotinib demonstrating increased staining most appreciated in the dermal melanocytes.”
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